

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

Supplemental Table 1. Treatment characteristics and short-term outcomes in 74 patients who underwent distal ureterectomy for upper tract urothelial carcinoma at Skåne University Hospital between 2004-2022.

Variable	Outcome
Operating time median (IQR) minutes	300 (280-400)
Blood loss median (IQR) ml	150 (100-200)
Perioperative lymphadenectomy	29 (39)
Bladder cuff removal	68 (92)
Robotic assisted laparoscopic DU	1 (1)
Antirefluxing reimplantation	34 (46)
Negative surgical margins [†]	63 (85)
Pathologic tumour stage ≥T2	17 (23)
Presence of carcinoma in situ in ureterectomy specimen	17 (23)
Lymph node metastasis in lymphadenectomy specimen	4 (5)
Pathological tumour grade (WHO 1999)	
GX	2 (3)
G1	3 (4)
G2	38 (51)
G3	31 (42)
Length of stay (IQR) days	8 (6-9)
90-day complications according to Clavien-Dindo	
Grade 0	33 (45)
Grade 1	6 (8)
Grade 2	25 (34)
Grade 3a*	7 (10)
Grade 3b**	1 (1)
Grade 4***	1 (1)
Grade 5****	1 (1)
Unplanned hospital readmission within 90 days	11 (15)
Adjuvant oncological therapy	
Radiotherapy ^{††}	1 (1)
Chemotherapy ^{†††}	3 (4)

IQR = Inter Quartile Range DU = Distal Ureterectomy. [†] Uncertain margin (n=3). Positive margin (n= 8, of which 6 had positive lateral margins and two had positive proximal or distal ureteric margin).

*Pulmonary embolism requiring vena cava filter (2 patients), lymphocele requiring percutaneous drainage (5 patients). **Ileus treated with open surgery. ***Stroke. ****Sudden death from myocardial infarction. ^{††}50 Gy/25 fractions. ^{†††}One cycle cisplatin/gemcitabine followed by 4 cycles carboplatin/gemcitabine (1 patient), 4 cycles carboplatin/gemcitabine (1 patient) and 3 cycles carboplatin/gemcitabine (1 patient). Results are presented in numbers and proportions if not otherwise defined.

Supplemental Table 2. Outcomes in 12 patients with ipsilateral recurrence after distal ureterectomy.

Outcome	Nephroureterectomy (n=10)	Palliative treatment * (n=2)
pT after NU		
- Ta	7	-
- ≥T1	3	-
Location		
Ureter	3	1
Kidney	7	1
Number of tumours		
Single	5	1
Multiple or CIS**	5	1
Progression	0	2
Death by UTUC	0	2

NU = Nephroureterectomy, UTUC = Upper tract urotelial carcinoma.

*Patient not eligible for NU **CIS = Carcinoma in situ

Supplemental Table 3. Pathological findings in 26 patients undergoing ureteroscopy with biopsy before distal ureterectomy.

Stage	N (%)	Grade 1	Grade 2	Grade 3
T0	2 (8)	-	-	-
Tx	5 (19)*	0	3	0
Ta	12 (46)	2	8	2
T1	5 (19)**	0	2	3
CIS	2 (8)	-	-	2

*Two biopsies were not possible to grade **One biopsy showed concomitant carcinoma in situ (CIS).